We then provide an up-to-date overview of the nanomaterial-based approach to deliver small molecular inhibitors for regulating the activity of HSP and glucose oxidase for regulating the metabolic pathway, which can be used to increase the efficacy of PTT/PDT or in combination cancer therapy. This evidence concerns the gene HSP90B2P and cancer.